azacitidine has been researched along with Thrombocytopenia in 41 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.88) | 18.7374 |
| 1990's | 2 (4.88) | 18.2507 |
| 2000's | 4 (9.76) | 29.6817 |
| 2010's | 20 (48.78) | 24.3611 |
| 2020's | 13 (31.71) | 2.80 |
| Authors | Studies |
|---|---|
| Aoyama, S; Inoue, S; Kasahara, S; Makino, T; Mizui, T; Morita, M; Nagaya, K; Osawa, T; Tachi, T; Tanaka, K; Teramachi, H; Watanabe, H; Yasuda, M | 1 |
| Bartholdy, BA; Benard, L; Choudhary, G; Cole, S; DeFronzo, S; Heckman, CA; Javarappa, KK; Okoye-Okafor, UC; Pallaud, C; Ramos, PM; Ruiz, S; Saad, J; Shastri, A; Tatiparthy, M; Thiruthuvanathan, VJ; Tsallos, D; Verma, A; Will, B; Yang, D; Zhang, C | 1 |
| Sekeres, MA; Taylor, J | 1 |
| Choi, EJ; Hong, J; Kim, YJ; Lee, JH; Lee, KH; Park, S; Park, SY; Shin, DY; Yoon, SS | 1 |
| Arnan, M; Baer, MR; Brevard, J; Cortes, JE; De Botton, S; Dinner, SN; Donnellan, W; Ferrell, PB; Forsyth, S; Guichard, SM; Henrick, P; Jonas, BA; Kelly, P; Lee, S; Marzac, C; Mohamed, H; Montesinos, P; Pigneux, A; Prebet, T; Récher, C; Schiller, GJ; Schwarer, AP; Seiter, KP; Sweeney, J; Wang, ES; Watts, JM; Wei, AH; Yang, J | 1 |
| Demir, AM; Demirci, U; Iflazoglu, H; Kirkizlar, O; Kirkizlar, TA; Umit, EG; Umut, A | 1 |
| Altman, JK; Attar, EC; Fathi, AT; Garcia-Manero, G; Goldberg, AD; Hickman, DK; Kanagal-Shamanna, R; Kantarjian, H; Komrokji, R; Lancet, J; Miller, C; Odenike, O; Roboz, GJ; Sallman, DA; Sweet, K; Wennborg, A; Winer, ES | 1 |
| Al Ali, N; Duong, VH; Komrokji, RS; Lancet, JE; List, AF; Padron, E; Sallman, D; Zhang, L | 1 |
| DiNardo, CD; Döhner, H; Esteve, J; Fenaux, P; Garcia, JS; Hájek, R; Havelange, V; Hong, WJ; Illés, Á; Jang, JH; Jonas, BA; Koller, E; Konopleva, M; Lavie, D; Leber, B; Lemoli, RM; Letai, A; Pejsa, V; Porkka, K; Potluri, J; Pratz, KW; Pullarkat, V; Thirman, MJ; Turgut, M; Wang, J; Wei, AH; Yamamoto, K; Yeh, SP; Yoon, SS; Zhou, Y | 1 |
| Arbelbide, J; Belli, CB; Crisp, R; Di Stefano, M; Enrico, A; Espinosa, D; González, J; Iastrebner, M; Lazzarino, C; Perusini, MA; Pimentel, M; Pintos, N; Rosenhain, M; Schuster, S; Serrano, JC; Tavares, R | 1 |
| Ajib, S; Bornhäuser, M; Bug, G; Crysandt, M; Dressler, S; Haas, R; Hausmann, A; Heidenreich, D; Hirschbühl, K; Hoepting, M; Jost, E; Kaivers, J; Klein, S; Kobbe, G; Koldehoff, M; Kordelas, L; Kriege, O; Müller, LP; Rautenberg, C; Schaffrath, J; Schmid, C; Schroeder, T; Schuler, E; Wagner-Drouet, EM; Wolff, D | 1 |
| Bowen, D; Cargo, C; Culligan, D; Enright, H; Green, S; Ingram, W; Jones, GL; Kell, J; Killick, SB; Krishnamurthy, P; Kulasekararaj, A; Mills, J; Mufti, G; Payne, EM; Quek, L; Raghavan, M; Stanworth, SJ; Sternberg, A; Wiseman, DH | 1 |
| Bailey, R; Beach, CL; Chevassut, T; Döhner, H; Dombret, H; Figuera-Alvarez, A; Hiwase, D; La Torre, I; Montesinos, P; Musso, M; Pierdomenico, F; Pocock, C; Ravandi, F; Roboz, GJ; Safah, H; Sayar, H; Selleslag, D; Skikne, B; Sohn, SK; Tse, W; Wei, AH; Zhong, J | 1 |
| Dodillet, H; Kreuzer, KA; Monsef, I; Skoetz, N | 1 |
| Gao, Y; Gong, M; Kong, X; Ma, Y; Zhang, C | 1 |
| Hanamoto, H; Ishikawa, J; Kawata, S; Maeda, Y; Matsuda, M; Matsumura, I; Morita, Y; Shibayama, H; Tsubaki, K; Urase, F; Yamaguchi, T | 1 |
| Douvali, E; Kotsianidis, I; Papadopoulos, V; Papoutselis, M; Spanoudakis, E; Tsatalas, C; Vassilakopoulos, TP | 1 |
| Adès, L; Ame, S; Beyne-Rauzy, O; Braun, T; Charbonnier, A; Delaunay, J; Dreyfus, F; Fenaux, P; Prebet, T; Raffoux, E; Stammatoullas, A; Vey, N; Wattel, E | 1 |
| Egle, A; Melchardt, T; Weiss, L | 1 |
| Cherif, H; Chowdhury, O; Garelius, H; Hellström-Lindberg, E; Jacobsen, SE; Lorenz, F; Saft, L; Svensson, T | 1 |
| Li, J; Liu, J; Su, C; Tong, X; Zheng, D; Zhou, Z | 1 |
| Feng, Q; Hou, M; Hou, Y; Li, G; Li, L; Liu, X; Min, Y; Ni, H; Peng, J; Qiu, J; Shao, L; Wang, Y; Xu, S; Yang, L; Zhang, X; Zhou, H | 1 |
| De Castro, CM; Griffin, PT; Komrokji, RS; Lancet, JE; List, AF; Melchert, M; Rizzieri, DA | 1 |
| Chen, J; Han, Y; Liang, J; Ruan, C; Tang, Y; Wu, D; Ye, C | 1 |
| Gomes de Souza, VH; Moura, CA; Moura, CG; Neto, J; Santiago, M | 1 |
| Altman, J; Dinner, S; Frankfurt, O; Gao, J; Helenowski, I; McMahon, BJ; Stein, BL; Waisbren, J | 1 |
| Bellet, RE; Laucius, JF; Mastrangelo, MJ; Stambaugh, JE; Weiss, AJ | 1 |
| Lachs, MS; Ritchie, EK | 1 |
| Andritsos, L; Baiocchi, R; Benson, DM; Blum, KA; Byrd, JC; Chan, KK; Chen, P; Devine, SM; Flynn, J; Grever, MR; Jones, J; Liu, Z; Lucas, DM; Marcucci, G; Plass, C; Xie, Z | 1 |
| Aggerholm, A; Antunovic, P; Astermark, J; Bernell, P; Engström, LM; Grövdal, M; Hellström-Lindberg, E; Hokland, P; Holm, MS; Jacobsen, SE; Karimi, M; Khan, R; Kjeldsen, L; Linder, O; Nilsson, L; Oberg, G; Olsson, A; Porwit, A; Tangen, JM; Wallvik, J | 1 |
| Berger, DP; Franklin, JL; Gabrilove, JL; Garcia-Manero, G; Giles, FJ; Greenberg, PL; Hu, K; Kantarjian, HM; Paquette, RL; Wang, ES | 1 |
| Li, Z; Wang, J; Wang, S; Yi, Z | 1 |
| Al-Ali, HK; Cross, M; Hoppe, G; Jaekel, N; Junghanss, C; Krahl, R; Maschmeyer, G; Niederwieser, D | 1 |
| Arthur, C; Buckstein, R; Cermak, J; Chou, WC; Delaunay, J; Dmoszynska, A; Faderl, S; Gau, JP; Kantarjian, HM; Kuo, CY; Lysák, D; Mayer, J; Mazur, G; Minden, M; Oriol, A; Ravandi, F; Thomas, XG; Wierzbowska, A | 1 |
| Akria, L; Arad, A; Aviv, A; Braester, A; Dally, N; Filanovsky, K; Gafter-Gvili, A; Gatt, ME; Hellmann, I; Herishanu, Y; Herzog-Tzarfati, K; Leiba, R; Merkel, D; Mittelman, M; Nagler, A; Nemets, A; Ofran, Y; Ronson, A; Rouvio, O; Silbershatz, I; Tadmor, T; Vidal, L; Yeganeh, S | 1 |
| Evans, C; Gryn, J; Lister, J; Meisner, D; Raymond, JM; Sbeitan, I; Shadduck, RK; Srodes, C; Zeigler, ZR | 1 |
| Sumida, KN; Suwanawiboon, B | 1 |
| Glaubiger, DL; LeVine, AS; Poplack, DG; Reaman, GH; Srinivasan, U | 1 |
| Berger, EG | 1 |
| Gabrilove, JL | 1 |
| Ben-Baruch, N; Cowan, KH; Fine, R; Ford, H; Kelley, JA; Surbone, A; Thomas, RV | 1 |
5 review(s) available for azacitidine and Thrombocytopenia
| Article | Year |
|---|---|
Diagnosis and Treatment of Myelodysplastic Syndromes: A Review.
Topics: Antineoplastic Agents; Azacitidine; Decitabine; Erythropoietin; Female; Hematinics; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Neutropenia; Prognosis; Thrombocytopenia | 2022 |
Thrombopoietin mimetics for patients with myelodysplastic syndromes.
Topics: Adult; Azacitidine; Benzoates; Blood Transfusion; Decitabine; Female; Hemorrhage; Humans; Hydrazines; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Pyrazoles; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Thalidomide; Thrombocytopenia; Thrombopoietin | 2017 |
5-azacitidine: An alternative treatment of myelodysplastic syndromes in patient with refractory response to hematopoietic growth factor, a case report and review of literatures.
Topics: Aged; Anemia; Antimetabolites, Antineoplastic; Azacitidine; Blood Transfusion; Erythropoietin; Hematopoietic Cell Growth Factors; Humans; Male; Myelodysplastic Syndromes; Thrombocytopenia | 2004 |
Tn-syndrome.
Topics: Anemia, Hemolytic; Antibodies, Monoclonal; Antigens, Neoplasm; Antigens, Tumor-Associated, Carbohydrate; Azacitidine; Blood Cells; Erythrocyte Membrane; Galactosyltransferases; Hematologic Diseases; Humans; Lectins; Leukopenia; Molecular Structure; Syndrome; Thrombocytopenia | 1999 |
Hematologic malignancies: an opportunity for targeted drug therapy.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Azacitidine; DNA, Neoplasm; Erythropoietin; Hematologic Neoplasms; Humans; Recombinant Proteins; Thrombocytopenia | 2001 |
18 trial(s) available for azacitidine and Thrombocytopenia
| Article | Year |
|---|---|
Five-day versus 7-day treatment regimen with azacitidine in lower risk myelodysplastic syndrome: A phase 2, multicenter, randomized trial.
Topics: Adult; Antimetabolites, Antineoplastic; Azacitidine; Blood Transfusion; Humans; Middle Aged; Myelodysplastic Syndromes; Thrombocytopenia; Treatment Outcome | 2022 |
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Febrile Neutropenia; Female; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Thrombocytopenia | 2023 |
Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Thrombocytopenia; Treatment Outcome; Tumor Suppressor Protein p53 | 2023 |
A sequential two-stage dose escalation study of eltrombopag in patients with myelodysplastic syndrome and thrombocytopenia after hypomethylating agent failure.
Topics: Azacitidine; Benzoates; Humans; Hydrazines; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazoles; Thrombocytopenia; Treatment Outcome | 2020 |
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Double-Blind Method; Female; Follow-Up Studies; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukopenia; Male; Middle Aged; Pneumonia; Recurrence; Remission Induction; Sulfonamides; Thrombocytopenia | 2020 |
Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Azacitidine; Disease Management; Female; Gastrointestinal Diseases; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Placebo Effect; Remission Induction; Thrombocytopenia | 2021 |
Five-day regimen of azacitidine for lower-risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single-arm phase 2 trial.
Topics: Aged; Aged, 80 and over; Anemia, Refractory; Anemia, Sideroblastic; Antimetabolites, Antineoplastic; Azacitidine; Blood Component Transfusion; Drug Administration Schedule; Feasibility Studies; Febrile Neutropenia; Female; Humans; Japan; Male; Middle Aged; Prospective Studies; Thrombocytopenia; Treatment Outcome | 2018 |
Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Hydroxamic Acids; In Vitro Techniques; Middle Aged; Myelodysplastic Syndromes; Nausea; Neutropenia; Recurrence; Risk Factors; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vomiting; Vorinostat | 2014 |
A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Azacitidine; Benzoates; Blood Platelets; Cell Cycle; Drug Synergism; Drug Therapy, Combination; Female; Hematopoietic Stem Cells; Humans; Hydrazines; Ischemic Attack, Transient; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Platelet Count; Pyrazoles; Receptors, Thrombopoietin; Remission Induction; Thrombocytopenia; Treatment Outcome; Venous Thrombosis | 2014 |
A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy.
Topics: Aged; Aged, 80 and over; Anthracyclines; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Female; Humans; Induction Chemotherapy; Injections, Subcutaneous; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Pilot Projects; Remission Induction; Survival Analysis; Thrombocytopenia | 2015 |
Low-Dose Decitabine for Patients With Thrombocytopenia Following Allogeneic Hematopoietic Stem Cell Transplantation: A Pilot Therapeutic Study.
Topics: Azacitidine; Blood Platelets; Bone Marrow Examination; China; Decitabine; Hematopoietic Stem Cell Transplantation; Humans; Pilot Projects; Platelet Count; Thrombocytopenia; Time Factors; Transplantation, Homologous; Treatment Outcome | 2015 |
Phase I study of 5-azacytidine (NSC-102816) .
Topics: Antimetabolites, Antineoplastic; Aspartate Aminotransferases; Azacitidine; Female; Humans; Leukopenia; Male; Remission Induction; Thrombocytopenia; Time Factors; Treatment Outcome | 1972 |
Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Thrombocytopenia; Treatment Outcome | 2010 |
Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; DNA Methylation; DNA, Neoplasm; Drug Administration Schedule; Epidemiologic Methods; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Polymerase Chain Reaction; Promoter Regions, Genetic; Remission Induction; Thrombocytopenia; Treatment Outcome | 2010 |
Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Incidence; Male; Middle Aged; Myelodysplastic Syndromes; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin | 2010 |
Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Constipation; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Leukemia, Myeloid; Male; Middle Aged; Nausea; Neutropenia; Prospective Studies; Remission Induction; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2012 |
Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Choice Behavior; Cytarabine; Decision Making; Decitabine; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Neutropenia; Palliative Care; Patient Participation; Remission Induction; Risk Assessment; Risk Factors; Thrombocytopenia; Treatment Outcome | 2012 |
Phase I and pharmacokinetic study of arabinofuranosyl-5-azacytosine (fazarabine, NSC 281272).
Topics: Adult; Aged; Antineoplastic Agents; Azacitidine; Clinical Trials as Topic; Drug Administration Schedule; Drug Evaluation; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia | 1990 |
18 other study(ies) available for azacitidine and Thrombocytopenia
| Article | Year |
|---|---|
Risk factors for thrombocytopenia and analysis of time to platelet transfusion after azacitidine treatment.
Topics: Azacitidine; Humans; Myelodysplastic Syndromes; Platelet Transfusion; Risk Factors; Thrombocytopenia | 2021 |
Megakaryopoiesis impairment through acute innate immune signaling activation by azacitidine.
Topics: Azacitidine; Humans; Immunity, Innate; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thrombocytopenia | 2022 |
Incidence and predisposing factors of infection in patients treated with hypomethylating agents.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Causality; Female; Humans; Incidence; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Myelodysplastic Syndromes; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2023 |
Severe thrombocytopenia as a predictor of survival and response to hypomethylating agents in myelodysplastic syndromes: A Latin-American cohort of 212 patients.
Topics: Aged; Azacitidine; Databases, Factual; Disease-Free Survival; Female; Follow-Up Studies; Humans; Latin America; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Severity of Illness Index; Survival Rate; Thrombocytopenia | 2020 |
Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
Topics: Allografts; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Combined Modality Therapy; Decitabine; DNA Methylation; Drug Evaluation; Febrile Neutropenia; Germany; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukocyte Count; Myelodysplastic Syndromes; Recurrence; Retrospective Studies; Salvage Therapy; Sulfonamides; Thrombocytopenia; Transplantation Conditioning; Tumor Lysis Syndrome | 2021 |
British Society for Haematology guidelines for the management of adult myelodysplastic syndromes.
Topics: Adult; Anemia; Antineoplastic Agents; Azacitidine; Blood Transfusion; Decitabine; Disease Management; Hematinics; Hematopoietic Stem Cell Transplantation; Hemorrhage; Humans; Iron Chelating Agents; Myelodysplastic Syndromes; Neutropenia; Thrombocytopenia | 2021 |
Successful eltrombopag treatment of severe refractory thrombocytopenia in chronic myelomonocytic leukemia: Two cases reports: A CARE-compliant article.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Benzoates; Decitabine; Dioxygenases; DNA-Binding Proteins; Drug Monitoring; Female; Hematologic Agents; Humans; Hydrazines; Leukemia, Myelomonocytic, Chronic; Middle Aged; Mutation; Nuclear Proteins; Platelet Count; Proto-Oncogene Proteins; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Ribonucleoproteins; Serine-Arginine Splicing Factors; Thrombocytopenia; Thrombopoietin; Treatment Outcome | 2017 |
Safety and efficacy of 5-azacytidine treatment in myelodysplastic syndrome patients with moderate and mild renal impairment.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Disease-Free Survival; Drug Administration Schedule; Female; Glomerular Filtration Rate; Humans; Infections; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Remission Induction; Renal Insufficiency; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2013 |
[Autoimmune hemolysis accompanied by thrombopenia: consumption or myelodysplasia?].
Topics: Aged; Anemia, Hemolytic, Autoimmune; Antimetabolites, Antineoplastic; Azacitidine; Biopsy, Needle; Bone Marrow; Diagnosis, Differential; Disease Progression; Follow-Up Studies; Humans; Leukopenia; Male; Myelodysplastic Syndromes; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Thrombocytopenia | 2013 |
Efficacy and side-effects of decitabine in treatment of atypical chronic myeloid leukemia.
Topics: Adult; Anemia; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Aberrations; Decitabine; Fatal Outcome; Female; Humans; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Remission Induction; Thrombocytopenia; Treatment Outcome | 2015 |
Low-dose decitabine promotes megakaryocyte maturation and platelet production in healthy controls and immune thrombocytopenia.
Topics: Adolescent; Adult; Aged; Azacitidine; Base Sequence; Blood Platelets; Case-Control Studies; Cell Differentiation; CpG Islands; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Flow Cytometry; Humans; Male; Megakaryocytes; Middle Aged; Molecular Sequence Data; Promoter Regions, Genetic; Purpura, Thrombocytopenic, Idiopathic; Thrombocytopenia; TNF-Related Apoptosis-Inducing Ligand; Young Adult | 2015 |
Chronic myelomonocytic leukemia mimicking hematologic systemic lupus erythematosus.
Topics: Aged, 80 and over; Antibodies, Antinuclear; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers; Bone Marrow Examination; Diagnosis, Differential; Female; Hemolysis; Humans; Leukemia, Myelomonocytic, Chronic; Lupus Erythematosus, Systemic; Predictive Value of Tests; Thrombocytopenia | 2017 |
Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Benzoates; Decitabine; Female; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Risk; Thrombocytopenia; Thrombopoietin | 2017 |
Management of myelodysplastic syndromes in the geriatric patient.
Topics: Aged; Anemia; Antineoplastic Agents; Azacitidine; Decitabine; Erythrocyte Transfusion; Erythropoietin; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Neutropenia; Thalidomide; Thrombocytopenia | 2009 |
The effect of decitabine on megakaryocyte maturation and platelet release.
Topics: Animals; Azacitidine; Blood Platelets; Bone Marrow Cells; Cell Differentiation; Cell Line; Decitabine; DNA Methylation; Fetal Blood; Humans; In Vitro Techniques; Megakaryocytes; Mice; Myelodysplastic Syndromes; Platelet Count; Polyploidy; Thrombocytopenia; Thrombopoiesis; Up-Regulation | 2011 |
Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Aberrations; Disease Susceptibility; Female; Humans; Incidence; Infections; Israel; Leukemia, Myeloid, Acute; Male; Methylation; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Retrospective Studies; Risk Factors; Severity of Illness Index; Thrombocytopenia | 2013 |
Treatment of myelodysplastic syndromes with 5-azacytidine.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Azacitidine; Blood Transfusion; Female; Humans; Leukocytes; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2002 |
Phase II study of 5-azacytidine in sarcomas of bone.
Topics: Adolescent; Adult; Azacitidine; Bone Neoplasms; Drug Administration Schedule; Drug Evaluation; Female; Humans; Leukocyte Count; Male; Neoplasm Metastasis; Neutropenia; Osteosarcoma; Platelet Count; Sarcoma, Ewing; Thrombocytopenia | 1982 |